Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center
PharmaEssentia Japan K.K.
Incyte Corporation
Protagonist Therapeutics, Inc.
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
PharmaEssentia Japan K.K.
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Vanderbilt-Ingram Cancer Center
Ottawa Hospital Research Institute
Novartis
Federico II University
Protagonist Therapeutics, Inc.
Queen's University, Belfast
University Health Network, Toronto
M.D. Anderson Cancer Center
Thomas Jefferson University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University Hospital, Bordeaux
Novartis
Hoffmann-La Roche
Northwestern University
Roswell Park Cancer Institute
Novartis
Icahn School of Medicine at Mount Sinai
Incyte Corporation
University Hospital, Geneva
Case Comprehensive Cancer Center
University Hospital, Bordeaux
Novartis
Canadian Cancer Trials Group
Fred Hutchinson Cancer Center
Mayo Clinic
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Italfarmaco
Italfarmaco
Mayo Clinic
University of Utah
Roswell Park Cancer Institute
Icahn School of Medicine at Mount Sinai
Italfarmaco
Novartis
Icahn School of Medicine at Mount Sinai
M.D. Anderson Cancer Center
Incyte Corporation
Icahn School of Medicine at Mount Sinai